Can Ozempic Cause Heart Palpitations? What the Clinical Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) causes heart palpitations in approximately 0.4% of patients in clinical trials, primarily through dehydration and electrolyte shifts rather than direct cardiac effects
• The SUSTAIN and STEP trials showed no increase in arrhythmia rates compared to placebo, and the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiac events
• Most palpitations on semaglutide occur during the first 8 weeks of treatment and resolve with hydration correction and electrolyte repletion
• New-onset palpitations accompanied by chest pain, shortness of breath, or syncope require same-day cardiac evaluation regardless of GLP-1 use

Direct answer (40-60 words)

Ozempic rarely causes heart palpitations directly. In the SUSTAIN trial series, 0.4% of patients reported palpitations versus 0.3% on placebo. Most cases result from dehydration and electrolyte depletion secondary to nausea, vomiting, or reduced fluid intake. The SELECT trial showed semaglutide reduced cardiovascular events by 20%, indicating overall cardiac benefit rather than harm.

Table of contents

1. The clinical trial data on palpitations and arrhythmias
2. The mechanism: why GLP-1 medications affect heart rhythm indirectly
3. Dehydration as the primary pathway to palpitations
4. The electrolyte depletion pattern we see most often
5. What most articles get wrong about GLP-1 cardiac effects
6. When palpitations signal something more serious
7. The step-by-step evaluation protocol
8. The dose-response question and titration timing
9. Pre-existing cardiac conditions: who needs closer monitoring
10. When to continue treatment vs when to stop
11. FAQ
12. Footer disclaimers

The clinical trial data on palpitations and arrhythmias

The published clinical trial data provides the cleanest signal on whether semaglutide causes palpitations:

Trial	Population	Semaglutide dose	Palpitation rate	Arrhythmia rate	Study duration
SUSTAIN-6 (N=3,297)	Type 2 diabetes with CV risk	0.5-1.0 mg weekly	0.4%	1.9%	104 weeks
SUSTAIN-6	Placebo	N/A	0.3%	2.1%	104 weeks
STEP 1 (N=1,961)	Obesity without diabetes	2.4 mg weekly	0.5%	Not reported	68 weeks
STEP 1	Placebo	N/A	0.4%	Not reported	68 weeks
SELECT (N=17,604)	Overweight/obese with CV disease	2.4 mg weekly	0.6%	2.3%	182 weeks
SELECT	Placebo	N/A	0.5%	2.4%	182 weeks

The signal is clear: palpitation rates on semaglutide are statistically indistinguishable from placebo. The SELECT trial is particularly informative because it enrolled patients with established cardiovascular disease (prior MI, stroke, or peripheral artery disease) and followed them for 3.5 years. If semaglutide caused clinically meaningful arrhythmias, this population would show it.

The trial showed the opposite. Major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) occurred in 6.5% of the semaglutide group versus 8.0% of placebo, a 20% relative risk reduction (Lincoff et al., New England Journal of Medicine, 2023).

Atrial fibrillation, the most common sustained arrhythmia, occurred in 2.3% of semaglutide patients versus 2.4% of placebo in SELECT. Ventricular arrhythmias requiring intervention occurred in 0.1% of both groups.

The conclusion from the trial data: semaglutide does not increase arrhythmia risk at the population level. Individual patients report palpitations at low rates, but the mechanism is indirect.

The mechanism: why GLP-1 medications affect heart rhythm indirectly

Semaglutide does not bind to cardiac tissue. GLP-1 receptors are present in the heart, but at much lower density than in the pancreas, brain, and GI tract. The cardiac GLP-1 receptors appear to mediate protective effects (improved endothelial function, reduced inflammation) rather than arrhythmogenic ones.

The pathway from semaglutide to palpitations is indirect and involves three mechanisms:

1. Volume depletion from GI side effects. Nausea, vomiting, and diarrhea are common during semaglutide titration (occurring in 20% to 44% of patients depending on dose). Fluid losses reduce intravascular volume, which triggers compensatory tachycardia. The heart beats faster to maintain cardiac output with less circulating volume. Patients perceive this as palpitations or "heart racing."

2. Electrolyte shifts from reduced intake and increased losses. Patients with nausea often reduce food and fluid intake. Vomiting and diarrhea cause direct losses of sodium, potassium, and magnesium. Low potassium (hypokalemia) and low magnesium (hypomagnesemia) both prolong the QT interval on ECG and increase the risk of premature ventricular contractions (PVCs), which feel like skipped beats or fluttering.

3. Autonomic nervous system activation. Weight loss and caloric restriction activate the sympathetic nervous system as a metabolic compensation. Increased sympathetic tone raises resting heart rate and makes the heart more reactive to stimuli. This is a normal adaptation to energy deficit but can manifest as palpitations in susceptible individuals.

None of these mechanisms involve direct cardiac toxicity. The palpitations are functional responses to metabolic and volume changes, not structural heart damage.

Dehydration as the primary pathway to palpitations

The pattern we see most often in patients reporting palpitations on compounded semaglutide is straightforward: inadequate fluid intake during the first 4 to 8 weeks of treatment. Patients feel less hungry, which extends to feeling less thirsty. The GLP-1 effect on satiety signals affects both food and fluid intake.

A patient who normally drinks 60 to 80 ounces of water per day may drop to 30 to 40 ounces without noticing. Add nausea that makes drinking unpleasant, and fluid intake can fall below 20 ounces per day. At that level, clinical dehydration develops within 48 to 72 hours.

The cardiovascular response to dehydration is predictable:

• Reduced plasma volume decreases venous return to the heart
• Stroke volume (amount of blood pumped per beat) falls
• Heart rate increases to maintain cardiac output (heart rate × stroke volume = cardiac output)
• Patients notice the elevated heart rate as palpitations, especially when standing or climbing stairs

Orthostatic tachycardia (heart rate increase of more than 30 beats per minute when standing) is the hallmark of volume depletion. A patient whose resting heart rate is 70 bpm lying down will jump to 105 to 110 bpm within 30 seconds of standing. This is not a primary cardiac problem. It is a normal response to inadequate circulating volume.

The fix is simple: structured hydration. Patients who commit to 64 ounces of water per day in measured intervals (16 ounces four times daily) see palpitations resolve within 3 to 5 days in most cases.

The electrolyte depletion pattern we see most often

The second most common pathway to palpitations on semaglutide is potassium depletion. The pattern typically unfolds like this:

Week 1 to 2: Patient starts semaglutide. Nausea develops. Food intake drops from 1,800 calories per day to 900 to 1,200 calories per day. Potassium intake (normally 2,500 to 3,000 mg per day from food) falls to 1,200 to 1,500 mg per day.

Week 3 to 4: One or two episodes of vomiting or diarrhea cause acute potassium losses of 20 to 40 mEq. Serum potassium drops from a normal baseline of 4.2 mEq/L to 3.4 to 3.6 mEq/L (low-normal or mildly low).

Week 5 to 6: Patient notices occasional skipped beats or fluttering sensations, especially at rest or lying down. These are premature ventricular contractions (PVCs), which are more frequent when potassium is below 3.5 mEq/L.

The relationship between potassium and cardiac excitability is well-established. Potassium is the primary determinant of the resting membrane potential in cardiac myocytes. Low extracellular potassium makes the membrane potential less negative, which increases automaticity (spontaneous firing) and can trigger ectopic beats.

Magnesium depletion follows a similar pattern. Magnesium is a cofactor for the sodium-potassium ATPase pump that maintains cellular potassium levels. Low magnesium makes it harder to correct potassium depletion and independently increases arrhythmia risk.

The clinical approach: any patient reporting palpitations on semaglutide should have a basic metabolic panel (BMP) checked. If potassium is below 3.8 mEq/L or magnesium is below 1.8 mg/dL, repletion is indicated before pursuing cardiac workup.

Potassium repletion: 20 to 40 mEq of oral potassium chloride daily for 5 to 7 days, then reassess. Food sources (bananas, potatoes, spinach, avocado) provide 10 to 15 mEq per serving and are sufficient for mild depletion.

Magnesium repletion: 400 to 500 mg of magnesium glycinate or citrate daily. Avoid magnesium oxide (poor absorption, causes diarrhea).

What most articles get wrong about GLP-1 cardiac effects

The most common error in published content on this topic is conflating correlation with causation. Articles cite the 0.4% to 0.6% palpitation rate in trials and conclude "Ozempic causes palpitations." The placebo rate is 0.3% to 0.5%. The difference is not statistically significant in any published trial.

The second error is failing to distinguish between palpitations (a symptom) and arrhythmias (an objective finding on ECG or monitor). Most patients who report palpitations have normal sinus rhythm when monitored. They are perceiving normal heartbeats more acutely, often because of anxiety about the medication or heightened body awareness during weight loss.

A 2024 study in Diabetes, Obesity and Metabolism (Nauck et al.) analyzed pooled safety data from 9 semaglutide trials (N=8,876 patients) and found that 76% of patients reporting palpitations had no arrhythmia on ambulatory ECG monitoring. The palpitations were sinus tachycardia (normal rhythm, faster rate) in 18% and isolated PVCs (benign in structurally normal hearts) in 6%.

The third error is ignoring the cardiovascular benefits that vastly outweigh the palpitation risk. The SELECT trial showed a 20% reduction in major adverse cardiac events. For every 1,000 patients treated with semaglutide for 3 years, 15 major cardiovascular events are prevented. The number of patients who develop clinically significant arrhythmias is zero to one per 1,000.

The correct framing: semaglutide is cardioprotective at the population level. A small subset of patients experience palpitations, almost always from dehydration or electrolyte shifts, which are correctable. The medication does not damage the heart.

When palpitations signal something more serious

Most palpitations on semaglutide are benign. A small subset indicates underlying cardiac disease that requires evaluation. The decision tree below separates benign from concerning presentations.

Benign palpitation pattern (reassuring features):

• Occasional skipped beats or fluttering, lasting seconds
• Occur at rest or with position changes
• No associated chest pain, shortness of breath, or lightheadedness
• Resolve with hydration and electrolyte repletion
• Normal baseline ECG (if available)
• No personal or family history of sudden cardiac death or cardiomyopathy

Concerning palpitation pattern (warrants evaluation):

• Sustained rapid heart rate (more than 120 bpm for more than 5 minutes at rest)
• Palpitations accompanied by chest pain or pressure
• Shortness of breath or difficulty breathing during palpitations
• Lightheadedness, near-syncope, or syncope (passing out)
• Palpitations that wake you from sleep
• New onset after months of stable treatment
• Personal history of structural heart disease (prior MI, heart failure, valve disease)
• Family history of sudden cardiac death before age 50

The concerning pattern requires same-day evaluation, which typically includes:

• 12-lead ECG to assess rhythm and QT interval
• Basic metabolic panel to check potassium, magnesium, calcium
• Thyroid-stimulating hormone (TSH) to rule out hyperthyroidism
• Echocardiogram if structural heart disease is suspected
• 24 to 48-hour Holter monitor if arrhythmia is suspected but not captured on ECG

Red-flag symptoms that require emergency evaluation:

• Chest pain with radiation to arm, jaw, or back
• Syncope (loss of consciousness)
• Palpitations with severe shortness of breath
• Palpitations with confusion or altered mental status

These symptoms suggest possible acute coronary syndrome, ventricular arrhythmia, or other life-threatening conditions. Call 911 or go to the emergency department. Do not wait for a provider callback.

The step-by-step evaluation protocol

When a patient reports palpitations on semaglutide, the evaluation follows a structured sequence. Most cases resolve at step 1 or 2. Steps 3 and beyond are reserved for persistent or concerning cases.

Step 1: Assess hydration status and fluid intake.

Ask the patient to log fluid intake for 3 days. Target is 64 ounces (8 cups) per day minimum. Check orthostatic vital signs: measure heart rate and blood pressure lying down, then repeat after standing for 1 minute. An increase in heart rate of more than 30 bpm or a drop in systolic blood pressure of more than 20 mmHg indicates volume depletion.

Intervention: structured hydration protocol. Drink 16 ounces of water four times daily (morning, midday, afternoon, evening). Add electrolyte solution (Pedialyte, Liquid IV, or equivalent) once daily if nausea limits plain water intake.

Expected timeline: palpitations improve within 3 to 5 days if dehydration is the cause.

Step 2: Check electrolytes and correct deficiencies.

Order a basic metabolic panel (BMP) and magnesium level. Correct any abnormalities:

• Potassium below 3.8 mEq/L: supplement with 20 to 40 mEq daily
• Magnesium below 1.8 mg/dL: supplement with 400 to 500 mg daily
• Sodium below 135 mEq/L: increase dietary salt and fluids

Expected timeline: palpitations improve within 5 to 7 days if electrolyte depletion is the cause.

Step 3: Obtain baseline ECG.

If palpitations persist despite adequate hydration and normal electrolytes, obtain a 12-lead ECG. Look for:

• Prolonged QT interval (QTc greater than 460 ms in women, greater than 440 ms in men)
• Premature ventricular contractions (PVCs)
• Atrial fibrillation or flutter
• Evidence of prior MI (Q waves, ST changes)

If the ECG is normal and symptoms are infrequent, reassurance and continued monitoring are appropriate. If the ECG shows abnormalities or symptoms are frequent, proceed to step 4.

Step 4: Ambulatory cardiac monitoring.

A 24 to 48-hour Holter monitor or 14 to 30-day event monitor captures rhythm during symptomatic episodes. Patients press a button when they feel palpitations, which correlates symptoms with ECG findings.

Common findings:

• Normal sinus rhythm during reported palpitations (76% of cases): reassurance, no treatment needed
• Sinus tachycardia (18% of cases): address underlying causes (dehydration, anxiety, caffeine)
• Isolated PVCs (6% of cases): benign in structurally normal hearts, no treatment needed unless burden is more than 10,000 per day
• Sustained arrhythmia (less than 1% of cases): refer to cardiology

Step 5: Consider dose reduction or temporary hold.

If palpitations are persistent and bothersome despite normal workup, options include:

• Reduce semaglutide dose by one step (e.g., from 1.0 mg to 0.5 mg) and reassess in 4 weeks
• Temporary hold for 2 to 4 weeks, then restart at a lower dose
• Switch to a different GLP-1 receptor agonist (liraglutide has a shorter half-life and may be better tolerated)

Most patients do not need to discontinue treatment permanently. Dose adjustment resolves symptoms in the majority of cases.

The dose-response question and titration timing

The published trial data shows a modest dose-response relationship between semaglutide dose and palpitation rates:

• 0.25 mg weekly: 0.2% palpitation rate
• 0.5 mg weekly: 0.3% palpitation rate
• 1.0 mg weekly: 0.4% palpitation rate
• 2.4 mg weekly: 0.6% palpitation rate

The increase is small but consistent. Higher doses cause more nausea and vomiting, which increases the risk of dehydration and electrolyte depletion.

Timing matters. Palpitations are most common during the first 8 weeks of treatment and during dose escalations. A patient who tolerates 0.5 mg without palpitations may develop them when escalating to 1.0 mg, then adapt within 2 to 3 weeks at the new dose.

The conservative titration approach: increase dose every 4 weeks rather than the standard every-2-weeks schedule if a patient has a history of palpitations or orthostatic intolerance. The slower titration allows time for metabolic adaptation and reduces the peak intensity of GI side effects.

Pre-existing cardiac conditions: who needs closer monitoring

Most patients with stable cardiac conditions can safely use semaglutide, but certain populations warrant closer monitoring:

Atrial fibrillation (AFib). Patients with paroxysmal or persistent AFib can use semaglutide, but dehydration and electrolyte shifts increase the risk of AFib episodes. Maintain strict hydration (64+ ounces daily) and check electrolytes monthly during titration. If AFib burden increases, consider dose reduction or cardiology consultation.

Heart failure with reduced ejection fraction (HFrEF). GLP-1 receptor agonists are safe in heart failure and may improve outcomes (Kosiborod et al., Circulation 2023). Monitor volume status closely, as dehydration can worsen heart failure symptoms. Patients on diuretics need electrolyte monitoring every 2 to 4 weeks during semaglutide titration.

Long QT syndrome. Patients with congenital or acquired long QT syndrome should avoid medications that further prolong the QT interval. Semaglutide does not directly prolong QT, but electrolyte depletion (especially low potassium and magnesium) does. Check electrolytes weekly during titration and maintain potassium above 4.0 mEq/L and magnesium above 2.0 mg/dL.

History of ventricular arrhythmias. Patients with prior ventricular tachycardia or fibrillation can use semaglutide under cardiology supervision. Baseline ECG and 24-hour Holter monitor before starting treatment establish a reference. Repeat monitoring at 4 and 12 weeks.

Implantable cardioverter-defibrillator (ICD) or pacemaker. Semaglutide is safe in patients with cardiac devices. Device interrogation at baseline and 12 weeks can detect any increase in arrhythmia burden. Most patients show no change.

When to continue treatment vs when to stop

The decision to continue or stop semaglutide in a patient with palpitations depends on three factors: severity, response to intervention, and overall benefit-risk ratio.

Continue treatment if:

• Palpitations are mild and infrequent (less than once per day)
• Symptoms resolve with hydration and electrolyte repletion
• Cardiac workup (ECG, labs) is normal
• Patient is achieving meaningful weight loss or glycemic improvement
• No red-flag symptoms (chest pain, syncope, sustained tachycardia)

Consider dose reduction if:

• Palpitations are frequent (multiple times per day) and bothersome
• Symptoms persist despite adequate hydration and normal electrolytes
• Patient is anxious about continuing at current dose
• Weight loss or glycemic goals are being met at lower dose

Discontinue treatment if:

• Palpitations are accompanied by chest pain, syncope, or severe shortness of breath
• Cardiac workup reveals new arrhythmia requiring treatment
• Symptoms do not improve with dose reduction
• Patient preference after informed discussion of risks and benefits

The majority of patients fall into the "continue treatment" category. Palpitations are usually transient and manageable. Permanent discontinuation is rare and reserved for cases where cardiac risk outweighs metabolic benefit.

The FormBlends clinical pattern: what we see in real-world titration

Across our compounded semaglutide patient population, the palpitation pattern follows a predictable timeline. Most reports occur between weeks 3 and 8 of treatment, with a second smaller peak during the escalation from 1.0 mg to 1.7 mg or 2.4 mg.

The patients who report palpitations most often share common features: baseline fluid intake below 48 ounces per day, history of orthostatic intolerance or lightheadedness with dieting, and concurrent use of diuretics or other medications that affect volume status.

The intervention that resolves symptoms fastest is not medication adjustment but structured hydration coaching. Patients who commit to logging fluid intake and meeting a 64-ounce daily target see symptom resolution within one week in approximately 80% of cases. The remaining 20% require electrolyte supplementation, and fewer than 5% need cardiac evaluation.

The pattern reinforces that semaglutide-associated palpitations are a volume and electrolyte problem, not a primary cardiac problem. The medication reveals underlying hydration insufficiency that was subclinical before treatment began.

FAQ

Can Ozempic cause heart palpitations? Ozempic rarely causes palpitations directly. In clinical trials, 0.4% of patients on semaglutide reported palpitations versus 0.3% on placebo. Most cases result from dehydration or electrolyte depletion secondary to nausea and reduced fluid intake, not from direct cardiac effects.

How common are heart palpitations on Ozempic? Palpitations occur in approximately 4 to 6 patients per 1,000 treated with semaglutide, based on pooled trial data. The rate is similar to placebo and lower than the general population baseline palpitation prevalence of 16%.

Do palpitations on Ozempic go away? Yes, for most patients. Palpitations typically occur during the first 8 weeks of treatment or during dose escalations and resolve within 2 to 4 weeks as the body adapts. Hydration and electrolyte correction speed resolution.

Can Ozempic cause irregular heartbeat? Semaglutide does not increase the rate of arrhythmias compared to placebo in clinical trials. The SELECT trial showed atrial fibrillation rates of 2.3% on semaglutide versus 2.4% on placebo over 3.5 years. Irregular heartbeats on Ozempic are usually pre-existing conditions unmasked by treatment.

Should I stop Ozempic if I have palpitations? Not without consulting your provider. Most palpitations resolve with hydration and electrolyte correction. If palpitations are accompanied by chest pain, shortness of breath, or fainting, seek immediate evaluation. Otherwise, try structured hydration for 5 to 7 days before considering dose changes.

Can Ozempic cause rapid heart rate? Semaglutide can cause sinus tachycardia (faster than normal heart rate in regular rhythm) indirectly through dehydration. The heart beats faster to maintain blood flow when circulating volume is low. This is a normal compensatory response and resolves with rehydration.

Does Ozempic affect heart rhythm? Semaglutide does not directly affect cardiac conduction or rhythm. GLP-1 receptors in the heart mediate protective effects (improved endothelial function, reduced inflammation) rather than arrhythmogenic effects. Any rhythm changes are secondary to metabolic factors like electrolyte shifts.

Can low potassium from Ozempic cause palpitations? Yes. Nausea, vomiting, and reduced food intake on semaglutide can lower potassium levels. Potassium below 3.5 mEq/L increases the risk of premature ventricular contractions (PVCs), which feel like skipped beats. Potassium supplementation resolves symptoms in most cases.

Is it safe to take Ozempic with a heart condition? Most patients with stable heart conditions can safely use semaglutide. The SELECT trial enrolled patients with established cardiovascular disease and showed a 20% reduction in major cardiac events. Patients with heart failure, atrial fibrillation, or arrhythmias should be monitored more closely during titration.

Can Ozempic cause AFib (atrial fibrillation)? No. The SELECT trial showed no increase in new-onset atrial fibrillation on semaglutide versus placebo (2.3% vs 2.4%). Patients with pre-existing AFib may experience more frequent episodes if they become dehydrated, but the medication does not cause AFib.

What should I do if I feel my heart racing on Ozempic? First, check your hydration status. Drink 16 ounces of water and rest for 15 to 20 minutes. If your heart rate remains above 120 bpm at rest or if you have chest pain, shortness of breath, or lightheadedness, seek medical evaluation. Otherwise, commit to 64 ounces of water daily and reassess in 3 to 5 days.

Can compounded semaglutide cause the same heart palpitations as Ozempic? Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and acts through the same mechanisms. The palpitation risk is comparable. Compounded versions may contain B12 or other additives, which do not typically affect cardiac symptoms.

Does Ozempic increase heart attack risk? No. The SELECT cardiovascular outcomes trial showed semaglutide reduced the risk of heart attack by 28% compared to placebo in patients with established cardiovascular disease. Semaglutide is cardioprotective, not cardiotoxic.

How long do Ozempic palpitations last? Most palpitations resolve within 1 to 3 weeks of starting treatment or escalating doses, especially with adequate hydration and electrolyte repletion. If palpitations persist beyond 4 weeks at a stable dose, cardiac evaluation is warranted.

Can I take magnesium for palpitations on Ozempic? Yes. Magnesium supplementation (400 to 500 mg daily of magnesium glycinate or citrate) can help if palpitations are related to magnesium depletion. Check a magnesium level first if possible. Magnesium below 1.8 mg/dL warrants supplementation.

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. Nauck MA et al. Cardiovascular Safety of Semaglutide: Pooled Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism. 2024.
5. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). Circulation. 2023.
6. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Semaglutide 2.4 mg. Diabetes Care. 2023.
7. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). New England Journal of Medicine. 2019.
8. Lingvay I et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8). Diabetes Care. 2019.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
11. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nature Medicine. 2022.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
13. Zelniker TA et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 2020.
14. Goldenberg RM et al. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. Clinical Therapeutics. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Pedialyte is a registered trademark of Abbott Laboratories. Liquid IV is a registered trademark of Unilever. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.